Structure via PubChem · Public domain (PubChem)
resiquimod
Sign in to saveAlso known as R-848, R848, R 848
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an
Chemical data
- Formula
- C17H22N4O2
- Molecular weight
- 314.4 g/mol
- IUPAC name
- 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
- SMILES
- CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
- InChIKey
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N
- XLogP
- 1.3
- Polar surface area
- 86.2 Ų
- H-bond donors
- 2
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- cutaneous melanoma, melanoma, metastatic melanoma, basal cell carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 314.174
Show 3 more facts
- Commons category
- Resiquimod
- chemical formula
- C₁₇H₂₂N₄O₂
- canonical SMILES
- CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.
== See also == Imiquimod Gardiquimod
Excerpted from Wikipedia’s “resiquimod” article, available under the CC BY-SA 4.0 licence.